Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, phase 2 trial enrolling patients with untreated
Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori